Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?

Core Insights - Moderna's shares increased by 13% following the announcement of preliminary sales for 2025 and business outlook for 2026 and beyond [2] - The company reported unaudited total revenues of $1.9 billion for 2025, exceeding the previous guidance range of $1.6-$2.0 billion [3] - Moderna expects operating expenses for 2025 to be between $5.0 billion and $5.2 billion, lower than the prior guidance of $5.2-$5.4 billion [3] Financial Performance - Moderna anticipates ending 2025 with cash and cash equivalents of $8.1 billion, an increase from the previous forecast of $6.5-$7.0 billion [4] - The company projects up to 10% revenue growth for 2026, with targeted operating expenses of approximately $4.9 billion [4] - For 2027, while no revenue guidance was provided, operating expenses are expected to be in the range of $4.2-$4.7 billion [5] Stock Performance - Year-to-date, Moderna's shares have risen by 20%, compared to the industry's growth of 19% [6] Pipeline and Milestones - Moderna has over 30 mRNA-based investigational candidates in various clinical stages, targeting multiple indications including cancer [9] - The company submitted regulatory filings for its seasonal influenza vaccine mRNA-1010 in several regions, with expectations for approval this year but a commercial launch anticipated next year [10] - Data readouts from late-stage studies on RSV and norovirus vaccines are expected before the end of this year [12] Oncology Focus - A key candidate in Moderna's pipeline is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, with a commercial launch targeted for next year [13] - Moderna is expanding its oncology pipeline, prioritizing the development of mRNA-4359, with a data readout expected before the end of 2026 [14]